Survey for women with CAH aged 25-64.
Are you a woman with a diagnosis of the condition congenital adrenal hyperplasia (CAH) aged between 25 and 64 years?
We are endocrinology doctors at Newcastle University in the UK investigating whether some women with this condition might find it more difficult to have cervical screening (aka smear tests). Previous studies (including the national audit of CAH – the CaHASE study) have shown that there can be issues with sexual function in women with CAH, and we are interested to see if this also applies to cervical screening.
We would be very grateful if you would consider completing the short anonymous survey below:
https://newcastle.onlinesurveys.ac.uk/cervical-screening-in-congenital-adrenal-hyperplasia
It should take less than 5 minutes and all answers are completely confidential (we will not ask for personal information that could identify you such as name, address or date of birth).
With thanks
Drs Kerri Devine and Anna Mitchell
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...